Managed care considerations

Area of Science:

• Neurology
• Pharmacoeconomics
• Cardiovascular Medicine

Background:

• Stroke is a leading cause of death and disability in the US, with ischemic strokes being the most common type.
• Transient ischemic attacks (TIAs) often precede strokes, and patients face a high risk of recurrent events, increasing disability and costs.
• Secondary prevention is crucial for stroke survivors to mitigate impairment and reduce healthcare expenditures.

Purpose of the Study:

• To discuss the burden of stroke on patients and caregivers.
• To review the risk of stroke recurrence and the role of antiplatelet therapy in secondary prevention.
• To analyze the pharmacoeconomics of antiplatelet agents for secondary stroke prevention.

Main Methods:

• Review of current guidelines for secondary stroke prevention, including recommendations from the American Heart Association/American Stroke Association.
• Analysis of clinical outcomes associated with antiplatelet therapy in patients with TIA or prior ischemic stroke.
• Pharmacoeconomic evaluation of aspirin (ASA), ASA + extended-release dipyridamole (DP), and clopidogrel.

Main Results:

• Updated guidelines recommend antiplatelet agents over anticoagulants for secondary prevention in ischemic noncardioembolic stroke or TIA.
• ASA, ASA + DP, and clopidogrel are identified as acceptable initial treatment options.
• Pharmacoeconomic analysis indicates that ASA and ASA + DP are cost-effective for secondary prevention in patients with mild initial strokes.

Conclusions:

• Effective secondary prevention with antiplatelet therapy can improve clinical outcomes and reduce the risk of recurrent stroke.
• ASA and ASA + DP represent cost-effective options for secondary stroke prevention, particularly for mild initial events.
• Optimizing antiplatelet therapy use can enhance clinical and economic outcomes, lessening the overall burden of cerebrovascular disease.